$23.11
0.59[2.62%]
At close: Apr 18
$23.11
0[0.00%]
After Hours: 5:28PM EDT
Jasper Therapeutics
(NASDAQ:JSPR)Jasper Therapeutics Stock (NASDAQ:JSPR), Analyst Ratings, Price Targets, Predictions
Jasper Therapeutics Inc has a consensus price target of $24.35, established from looking at the 32 latest analyst ratings. The last 3 analyst ratings were released from Evercore ISI Group, RBC Capital, and TD Cowen on April 3, 2024, March 28, 2024, and March 18, 2024. With an average price target of $45 between Evercore ISI Group, RBC Capital, and TD Cowen, there's an implied 94.72% upside for Jasper Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Evercore ISI Group
RBC Capital
TD Cowen
Oppenheimer
Cantor Fitzgerald
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Jasper Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/03/2024 | JSPR | Buy Now | Jasper Therapeutics | $23.11 | 181.26% | Evercore ISI Group | Gavin Clark-Gartner | → $65 | Initiates | → Outperform | Get Alert |
| 03/28/2024 | JSPR | Buy Now | Jasper Therapeutics | $23.11 | 202.9% | RBC Capital | Gregory Renza | → $70 | Initiates | → Outperform | Get Alert |
| 03/18/2024 | JSPR | Buy Now | Jasper Therapeutics | $23.11 | — | TD Cowen | Yaron Werber | — | Initiates | → Outperform | Get Alert |
| 03/07/2024 | JSPR | Buy Now | Jasper Therapeutics | $23.11 | 246.17% | Oppenheimer | Jay Olson | $80 → $80 | Maintains | Outperform | Get Alert |
| 10/12/2023 | JSPR | Buy Now | Jasper Therapeutics | $23.11 | -74.04% | Cantor Fitzgerald | Pete Stavropoulos | → $60 | Reiterates | Overweight → Overweight | Get Alert |
| 08/14/2023 | JSPR | Buy Now | Jasper Therapeutics | $23.11 | -82.69% | Credit Suisse | Judah Frommer | → $40 | Reiterates | Outperform → Outperform | Get Alert |
| 08/11/2023 | JSPR | Buy Now | Jasper Therapeutics | $23.11 | -69.71% | Capital One | Tim Chiang | → $70 | Initiates | → Overweight | Get Alert |
| 06/12/2023 | JSPR | Buy Now | Jasper Therapeutics | $23.11 | -70.36% | EF Hutton | Michael King | → $68.5 | Reiterates | Buy → Buy | Get Alert |
| 05/25/2023 | JSPR | Buy Now | Jasper Therapeutics | $23.11 | -70.36% | EF Hutton | Michael King | → $68.5 | Assumes | → Buy | Get Alert |
| 05/16/2023 | JSPR | Buy Now | Jasper Therapeutics | $23.11 | -65.38% | Oppenheimer | Jay Olson | → $80 | Reinstates | Outperform → Outperform | Get Alert |
| 05/15/2023 | JSPR | Buy Now | Jasper Therapeutics | $23.11 | -70.36% | EF Hutton | Michael King | → $68.5 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | JSPR | Buy Now | Jasper Therapeutics | $23.11 | -82.69% | Credit Suisse | Judah Frommer | → $40 | Reiterates | Outperform → Outperform | Get Alert |
| 03/09/2023 | JSPR | Buy Now | Jasper Therapeutics | $23.11 | -70.36% | EF Hutton | Michael King | → $68.5 | Reiterates | → Buy | Get Alert |
| 03/09/2023 | JSPR | Buy Now | Jasper Therapeutics | $23.11 | -74.04% | Cantor Fitzgerald | Pete Stavropoulos | → $60 | Reiterates | → Overweight | Get Alert |
| 03/09/2023 | JSPR | Buy Now | Jasper Therapeutics | $23.11 | -82.69% | Credit Suisse | Judah Frommer | → $40 | Reiterates | → Outperform | Get Alert |
| 02/27/2023 | JSPR | Buy Now | Jasper Therapeutics | $23.11 | -70.36% | EF Hutton | Michael King | → $68.5 | Reiterates | → Buy | Get Alert |
| 02/21/2023 | JSPR | Buy Now | Jasper Therapeutics | $23.11 | -70.36% | EF Hutton | Michael King | → $68.5 | Reiterates | → Buy | Get Alert |
| 02/17/2023 | JSPR | Buy Now | Jasper Therapeutics | $23.11 | -70.36% | EF Hutton | Michael King | → $68.5 | Reiterates | → Buy | Get Alert |
| 02/16/2023 | JSPR | Buy Now | Jasper Therapeutics | $23.11 | -70.36% | EF Hutton | Michael King | $40 → $68.5 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Jasper Therapeutics (JSPR)?
The latest price target for Jasper Therapeutics (NASDAQ: JSPR) was reported by Evercore ISI Group on April 3, 2024. The analyst firm set a price target for $65.00 expecting JSPR to rise to within 12 months (a possible 181.26% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Jasper Therapeutics (JSPR)?
The latest analyst rating for Jasper Therapeutics (NASDAQ: JSPR) was provided by Evercore ISI Group, and Jasper Therapeutics initiated their outperform rating.
When was the last upgrade for Jasper Therapeutics (JSPR)?
There is no last upgrade for Jasper Therapeutics.
When was the last downgrade for Jasper Therapeutics (JSPR)?
There is no last downgrade for Jasper Therapeutics.
When is the next analyst rating going to be posted or updated for Jasper Therapeutics (JSPR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Jasper Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Jasper Therapeutics was filed on April 3, 2024 so you should expect the next rating to be made available sometime around April 3, 2025.
Is the Analyst Rating Jasper Therapeutics (JSPR) correct?
While ratings are subjective and will change, the latest Jasper Therapeutics (JSPR) rating was a initiated with a price target of $0.00 to $65.00. The current price Jasper Therapeutics (JSPR) is trading at is $23.11, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.